A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19
Author:
Publisher
Informa UK Limited
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference42 articles.
1. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
2. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV
3. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
4. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses;Antiviral Research;2024-05
2. Structure and Ligand-based In Silico Studies towards the Natural Inhibitors against Receptor Recognition Spike Protein of SARS-CoV-2;The Open Bioinformatics Journal;2024-03-11
3. Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention;Stem Cells;2024
4. Identification of potential targets against SARS‐CoV‐2 of antiviral drugs based on photoaffinity probes;Drug Development Research;2023-05-11
5. Anti-HERV-K Drugs and Vaccines, Possible Therapies against Tumors;Vaccines;2023-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3